Identification of variants influences treatment decisions. Inhibitors of the poly-ADP-ribose polymerase (PARP) system, a pathway for repairing single-stranded DNA breaks, are recommended for tumors ...
Although prostate cancer is generally associated with favorable outcomes, metastatic disease remains incurable. Additionally, a subset of individuals with high-risk or metastatic disease are likely to ...
More evidence points to the benefits of germline genetic testing for patients with various cancers. Such testing can identify mutations that may warrant a change of treatment and allow trying a ...
Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its ...
Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...
A family history of prostate cancer has long been one of the few universally accepted risk factors for the disease. New findings now provide evidence that risk stratification based on family history ...
Up to 5% of Americans may carry genetic variants associated with cancer risk, according to a cross-sectional analysis.The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback